![]() |
市場調查報告書
商品編碼
1880633
安全胰島素筆針市場規模、佔有率、成長及全球產業分析:依類型、應用和地區劃分的洞察與預測(2024-2032 年)Safety Pen Needles Market Size, Share, Growth and Global Industry Analysis By Type & Application, Regional Insights and Forecast to 2024-2032 |
||||||
全球安全胰島素筆針市場正經歷穩定成長,這主要得益於糖尿病患者數量的增加、家庭醫療保健的普及以及對安全便捷的胰島素注射設備需求的不斷增長。 2024 年,該市場規模達到 7.224 億美元,主要受全球糖尿病負擔加重以及胰島素筆在慢性病管理中廣泛應用的推動。預計到 2025 年,該市場規模將達到 7.68 億美元,並在 2032 年顯著增長至 12.701 億美元,預測期內複合年增長率 (CAGR) 為 7.5%。北美是領先地區,在2024年佔全球市場佔有率的42.44%。
安全胰島素筆針是無菌一次性醫療器械,配備針頭保護罩和防護罩等防護功能,可防止針刺傷。其在臨床和家庭中的應用日益廣泛,主要歸功於其便利性、安全性以及與常用胰島素筆的兼容性。 Envector Corporation、Cardinal Health 和 MTD Medical Technology and Devices 等領先企業持續投資於創新、合作和新產品發布,從而鞏固其全球地位。
市場動態
市場推動因素
糖尿病盛行率的快速上升仍然是市場成長的主要推動因素。根據國際糖尿病聯盟 (IDF) 發布的 "糖尿病地圖集" (2025 年),目前 20 至 79 歲成年人中有 11.1% 患有糖尿病,這推動了對胰島素治療需求的成長。由於久坐的生活方式、肥胖以及快速的都市化進程,全球胰島素使用量持續成長。隨著患者和醫護人員尋求更安全的注射方式,安全胰島素筆針頭逐漸取代標準胰島素筆針頭和傳統注射器,成為更受歡迎的選擇。
市場限制因子
先進的替代給藥技術的出現對市場擴張構成了重大挑戰。無針給藥系統(例如鼻腔給藥和噴射注射器)的創新正日益受到患者和臨床醫生的關注。 2024年11月,Sol Millennium Medical Group在美國推出了Insujet無針胰島素輸注裝置,推動了非侵入性給藥方式的轉變。這可能會在未來幾年限制對安全胰島素筆針頭的需求。
市場機會
家庭醫療保健正成為成長最快的市場機會領域之一。根據NCBI(2023)的數據,全球約有60%的胰島素使用者傾向於使用胰島素筆自我注射。老年人群體尤其受益於胰島素筆針的便利性和安全性。遠距患者護理的擴展、個人化治療方案的推行以及小型胰島素筆設計的普及,正在推動胰島素筆的進一步推廣。亞太和拉丁美洲等新興市場家庭糖尿病管理的快速成長,蘊藏著巨大的未開發成長潛力。
市場挑戰
安全胰島素筆針的高昂成本仍然是其廣泛應用的一大障礙。正如英國國家醫療服務體系(NHS,2025年6月)所指出的,安全胰島素筆針的價格可能是標準針頭的八倍,而且在開發中地區通常不在醫療保險範圍內。在中國、印度和其他低收入市場,經濟承受能力有限仍然是其使用的主要阻礙因素。
市場趨勢
製造商正在整合先進的安全機制和超細針頭技術,以提高舒適度和患者依從性。 4毫米長、32-34號的胰島素筆針可以減輕注射疼痛,提升病患體驗。自動回縮機制、被動式防護罩和針頭隱藏系統正變得越來越受歡迎。此外,醫療器材公司和製藥公司之間的合作正在擴大胰島素和GLP-1受體激動劑更安全的注射系統範圍。
2024年,北美市場將以3.066億美元的估值引領市場,這主要得益於糖尿病的高發病率和強大的供應基礎。美國對生長激素療法的監管審批不斷增加,也推動了市場需求。歐洲市場佔有率位居第二,這主要歸功於處方量的成長和宣傳活動的擴大。亞太地區預計將實現最高的複合年增長率,這主要得益於該地區的高糖尿病發病率和新的分銷合作夥伴關係。拉丁美洲以及中東和非洲地區預計將保持穩定成長,這主要得益於肥胖率的上升以及先進藥物輸送裝置的普及。
The global safety pen needles market is witnessing consistent growth, driven by rising diabetes prevalence, expansion of home healthcare, and increasing preference for safe and convenient insulin delivery devices. The market was valued at USD 722.4 million in 2024, supported by the growing global burden of diabetes and high usage of insulin pens for chronic disease management. By 2025, the market is projected to reach USD 768.0 million, and by 2032, it is expected to expand significantly to USD 1,270.1 million, reflecting a CAGR of 7.5% during the forecast period. North America remained the dominant region in 2024, holding 42.44% of the global market share.
Safety pen needles are sterile, single-use devices engineered with protective mechanisms such as needle guards and shields to prevent accidental needlestick injuries. Their increasing adoption in clinical and home settings is largely attributed to their convenience, safety features, and compatibility with widely used insulin pens. Major companies such as Embecta Corp., Cardinal Health, and MTD Medical Technology and Devices continue to invest in technological upgrades, partnerships, and new product rollouts to strengthen their global presence.
Market Dynamics
Market Drivers
The sharp rise in diabetes prevalence remains the primary driver of market growth. The IDF Diabetes Atlas (2025) reports that 11.1% of adults aged 20-79 years are currently living with diabetes, highlighting the escalating demand for insulin therapy. Coupled with sedentary lifestyles, obesity, and rapid urbanization, the number of insulin users continues to grow worldwide. As patients and healthcare professionals seek safer injection methods, safety pen needles are increasingly preferred over standard pen needles and traditional syringes.
Market Restraints
The introduction of advanced alternative drug delivery technologies poses a significant challenge to market expansion. Innovations in needle-free systems-such as intranasal delivery and jet injectors-are gaining interest among patients and clinicians. In November 2024, Sol-Millennium Medical Group launched Insujet, a needle-free insulin delivery device in the U.S., representing a shift toward non-invasive drug delivery that may limit demand for safety pen needles in the coming years.
Market Opportunities
Home healthcare is emerging as one of the fastest-growing opportunity areas. According to NCBI (2023), around 60% of global insulin users prefer insulin pens for self-administration. The elderly population, in particular, benefits from the ease and safety of pen needles. Expanding remote patient care, personalized treatment plans, and availability of compact pen designs further support adoption. Emerging markets across Asia Pacific and Latin America are experiencing rapid increases in home-based diabetes management, presenting considerable untapped growth potential.
Market Challenges
The high cost of safety pen needles remains a barrier to widespread adoption. As noted by the NHS (June 2025), safety pen needles can be up to 8 times more expensive than standard needles and are often not reimbursed in developing regions. Limited affordability continues to restrict their use in China, India, and other low-income markets.
Market Trends
Manufacturers are integrating advanced safety mechanisms with ultra-thin needle technology to improve comfort and adherence. Pen needles with 4mm length and 32-34 gauge structures reduce injection pain and enhance patient experience. Auto-retraction, passive shielding, and hidden-needle systems are increasingly being incorporated. Furthermore, collaborations between medical device makers and pharmaceutical companies are expanding the availability of safety-enhanced injection systems for insulin and GLP-1 agonists.
North America led the market in 2024 with a valuation of USD 306.6 million, supported by high diabetes incidence and strong product availability. Increased regulatory approvals for growth hormone therapies in the U.S. also support demand. Europe held the second-largest share, with rising prescription volumes and growing awareness campaigns. Asia Pacific is projected to record the fastest CAGR, fueled by the region's high diabetes prevalence and new distribution partnerships. Latin America and Middle East & Africa are experiencing steady momentum, driven by rising obesity levels and expanding access to advanced drug delivery devices.
Conclusion
With market value rising from USD 722.4 million in 2024 to USD 1,270.1 million by 2032, the safety pen needles market demonstrates strong long-term growth potential. Demand will continue to be shaped by diabetes prevalence, home-care expansion, product innovation, and strategic industry partnerships, even as needle-free technologies create competitive pressure.
Segmentation By Product Type, Drug Type, Disease Indication, Needle Size, Distribution Channel, and Region
By Product Type * Active Safety Pen Needles
By Drug Type * Insulin
By Disease Indication * Diabetes
By Needle Size * 4 mm
By Distribution Channel * Hospital Pharmacy
By Region * North America (By Product Type, Drug Type, Disease Indication, Needle Size, Distribution Channel, and Country/Sub-region)
U.S.
Canada
U.K.
Germany
France
Italy
Spain
Scandinavia
Rest of Europe
China
Japan
India
Australia
Southeast Asia
Rest of Asia Pacific
Brazil
Mexico
Rest of Latin America
GCC
South Africa
Middle East & Africa